Anti-bacterial Peptides (SJ-12-0002)



Technology Name
(St. Jude Reference #)
Anti-bacterial Peptides
(SJ-12-0002)
Description Our researchers have derived peptides from the PB1-F2 protein of the influenza A virus that can be used to treat or prevent gram positive bacterial infection. These peptides have exhibited activity against a variety of medicinally important bacteria including Streptococcus pneumonia, Staphylococcus aureus and Streptococcus pyogenes. These peptides are expected to be effective against antibiotic resistant bacterial strains and do not cause inflammation.
Keywords Influenza, virulence, PB1-F2
Granted Patents or Published Applications U.S. provisional application pending.
Related Scientific References Alvmova, I.V. et al.,”Immunopathogenic and Antibacterial Effects of H3N2 Influenza A Virus PB1-F2 Map to Amino Acid Residues 62, 75, 79, and 82”, J. Virol. 85(23): 12324-12333 (Dec. 2011)
Licensing Opportunities We are currently seeking licensing opportunities for further development and testing of these peptides.
   

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: July 2012